119 related articles for article (PubMed ID: 10811451)
1. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma.
Vose JM; Colcher D; Gobar L; Bierman PJ; Augustine S; Tempero M; Leichner P; Lynch JC; Goldenberg D; Armitage JO
Leuk Lymphoma; 2000 Jun; 38(1-2):91-101. PubMed ID: 10811451
[TBL] [Abstract][Full Text] [Related]
2. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
4. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
5. 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
Lindén O; Tennvall J; Hindorf C; Cavallin-Ståhl E; Lindner KJ; Ohlsson T; Wingårdh K; Strand SE
Acta Oncol; 2002; 41(3):297-303. PubMed ID: 12195750
[TBL] [Abstract][Full Text] [Related]
6. 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma.
Becker WS; Behr TM; Cumme F; Rössler W; Wendler J; Kern PM; Gramatzki M; Kalden JR; Goldenberg DM; Wolf FG
Cancer Res; 1995 Dec; 55(23 Suppl):5771s-5773s. PubMed ID: 7493344
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
[TBL] [Abstract][Full Text] [Related]
9. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
[TBL] [Abstract][Full Text] [Related]
11. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
13. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
Newton DL; Hansen HJ; Mikulski SM; Goldenberg DM; Rybak SM
Blood; 2001 Jan; 97(2):528-35. PubMed ID: 11154233
[TBL] [Abstract][Full Text] [Related]
14. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
[TBL] [Abstract][Full Text] [Related]
16. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
Postema EJ; Raemaekers JM; Oyen WJ; Boerman OC; Mandigers CM; Goldenberg DM; van Dongen GA; Corstens FH
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3995S-4002S. PubMed ID: 14506199
[TBL] [Abstract][Full Text] [Related]
17. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma.
Arndt MA; Krauss J; Schwarzenbacher R; Vu BK; Greene S; Rybak SM
Int J Cancer; 2003 Dec; 107(5):822-9. PubMed ID: 14566834
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects.
Renner C; Trümper L; Pfreundschuh M
Leukemia; 1997 Apr; 11 Suppl 2():S55-9. PubMed ID: 9178842
[TBL] [Abstract][Full Text] [Related]
19. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
20. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.
Scheinberg DA; Straus DJ; Yeh SD; Divgi C; Garin-Chesa P; Graham M; Pentlow K; Coit D; Oettgen HF; Old LJ
J Clin Oncol; 1990 May; 8(5):792-803. PubMed ID: 2332769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
